Introduction: Diabetes mellitus is a complex, progressive disease, which is accompanied by multiple cardiovascular complications. Oxidative stress is significantly increased in diabetic patients and may lead to great haemostatic disturbances existing in these patients. The major thrust was to review current literature on potential interrelationships between haemostatic and metabolic abnormalities in diabetes mellitus. Zomoshin-6 decoction and Caragana jubata (Fabaceace) used in traditional Mongolian medicine have been shown to have haemostatic and antiviral effects. Objectives: The aim of this study was to examine the effect of Caragana jubata (Pall.) Poir. and Zomoshin-6 decoction on haemostatic parameters and lipid profiles in diabetic rats. Methods: Diabetes was induced in rats by using alloxan at a dose of 150 mg/kg. Control group received distilled water. Caragana jubata (Pall.) Poir and Zomoshin-6 were administered orally at doses of 2.0 g/kg and 0.2 g/kg respectively. Aspirin (100mg/kg) was used for comparison as a standard medicine. All treatments were performed daily for 3 weeks. Blood samples were obtained and analyzed for fibrinogen levels, prothrombin time, triglycerides (TG) and plasma uric acid. Results and conclusions: Levels of TG (p<0.05), glucose (p<0.03) and plasma uric acid (p<0.02) were increased in rats administered alloxan compare to control and these were significantly reduced by Caragana jubata and Zomoshin-6 treatments (Table 1). Caragana jubata and Zomoshin-6 significantly reduced increases in fibrinogen (p<0.05) level and prothrombin time induced by alloxan (Table 2). Table 1. Effect of Caragana jubata (Pall.) Poir and Zomoshin-6 on alloxan-induced increase in levels in TG, uric acid, and glucose. Table 2. Effect of Caragana jubata (Pall.) Poir and Zomoshin-6 on levels of fibrinogen and prothrombin time in rats given alloxan Parameters Control Alloxan 150 mg/kg Alloxan 150 mg/kg Caragana jubata 2.0 g/kg Zomoshin-6 tan 0.2 g/kg Aspirin 100 mg/kg Triglycerde ( mg/dl) 80.9±2.9 139.1±1.7 57±1.8* 64.0±2.5* 75±1.7* Uric acid (mg/dl)1.3±0.4 2.82±0.9 0.85±0.1* 0.9±0.2** 1.1±0.6* Glucose (mg/dl) 110.3±2.8 140±11 99.2±5*** 135.5±22* 125.2±31* Control Alloxan 150 mg/kg Alloxan 150 mg/kg Caragana jubata 2.0 g/kg Zomoshin-6 0.2 g/kg Aspirin 100 mg/kg Fibrinogen (g/l)221.2±8.7 254±3.7 264.3±4.0* 207.4±3.5** 168.4±1.9** Prothrombin time (sec) 14.1±4.6 9.57±0.3* 22.7±2.3* 22.8±0.7** 20.5±3

Introduction: Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disorder affecting multiple joints. Although etiology of RA is not fully understood, TNF-alpha has been shown to play a central role in the pathogenesis of RA. TNF-alpha stimulates proliferation of synovial cells and the production of matrix metalloproteinases by chondrocytes and synovial cells, and induces the release of other pro- inflammatory cytokines, leading to joint destruction. Objectives: The aim of the present study was to investigate the therapeutic effects of sunlavin, an arthritis relief tea on antigen- induced arthritis in rabbits. Methods: Arthritis of the knee joints was induced by ovalbumin injection into the joint spaces of pre-immunised rabbits. For time course experiments sunlavin was administered to rabbits for 7, 20, 34, and 49 days. Histopathological analysis of the synovial tissue was performed. Level of tumor necrosis factor-alpha (TNF-alpha), erythrocyte sedimentation rate (ESR), C reactive protein (CRP) level, and white blood cells count (WBC) were measured. Results: Sunlavin reduced joint swelling of antigen-induced arthritis model of rabbits. Histological examination revealed that sunlavin reduced edematous changes and infiltration of inflammatory cells in the synovial tissues. Increases in ESR, CRP, and WBC were reduced up to 52% by sunlavin. Moreover, sunlavin decreased blood level of TNF-alpha (21%) in rabbit model of antigen-induced arthritis suggesting that sunlavin ameliorates inflammatory response in arthritic joints by inhibiting THF-alpha. Discussions and conclusions: We speculate that the effect of sunlavin might be affected by the tissue environment and the disease state, that is, the effect of sunlavin on inflammation may change during the inflammatory process. Sunlavin can be a potential anti-inflammatory agent for acute and chronic phase of inflammation.